Kala Bio (KALA) Interest Expenses (2016 - 2025)
Kala Bio (KALA) posted Interest Expenses of $575000.0 for Q4 2025, down 40.29% sequentially from $963000.0 in Q3 2025, and down 58.69% YoY from $1.4 million in Q4 2024.
Kala Bio (KALA) Interest Expenses (2016 - 2025) Analysis & Trends
Kala Bio has reported Interest Expenses for 10 years, with the latest figure at $575000.0 in Q4 2025.
- Quarterly Interest Expenses fell 58.69% year-over-year to $575000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $2.6 million (down 51.67% YoY) and the FY2025 annual result came in at $146.9 million, up 5.27% from the prior year.
- Interest Expenses slipped to $575000.0 in Q4 2025 per KALA's latest filing, from $963000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $2.8 million in Q1 2021 and troughed at $269000.0 in Q4 2022.
- A 5-year average of $1.5 million and a median of $1.5 million in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2021 and 2023: Interest Expenses slumped 94.52% in 2021, then jumped 445.72% in 2023.
- Over 5 years, Interest Expenses stood at $2.2 million in 2021, then plunged by 87.49% to $269000.0 in 2022, then surged by 445.72% to $1.5 million in 2023, then slipped by 5.18% to $1.4 million in 2024, then plunged by 58.69% to $575000.0 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $575000.0, $963000.0, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 575,000.00 |
| Dec 31, 2025 | 575,000.00 |
| Sep 30, 2025 | 963,000.00 |
| Sep 30, 2025 | 963,000.00 |
| Jun 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 1.08 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 1.39 Mn |
| Dec 31, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.48 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Sep 30, 2023 | 1.46 Mn |